Arlan D. Martin
Arlan D. Martin has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abbie Wong
Pfizer, Inc., Bothell, Washington
52 shared publications - Alice P. Chin
Pfizer, Inc., Bothell, Washington
52 shared publications - Christopher M. Carosino
Pfizer, Inc., Bothell, Washington
52 shared publications - Courtney A.B. Karlsson
Pfizer, Inc., Bothell, Washington
52 shared publications - David J. Ortiz
Pfizer, Inc., Bothell, Washington
52 shared publications - Hao Sun
Pfizer Inc., Pharmacokinetics, Dynamics & Metabolism, Bothell, Washington
52 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 16 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 16. Production of proteases in culture by cancer cells is sufficient to activate SGN-CD47M to restore binding and function.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 16 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 16. Production of proteases in culture by cancer cells is sufficient to activate SGN-CD47M to restore binding and function.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 13. Assessment of the ability of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47, and a IgG1 isotype control antibody to induce direct apoptosis of THP1 cells, as assessed by flow cytometry of Annexin V cell surface expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 13. Assessment of the ability of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47, and a IgG1 isotype control antibody to induce direct apoptosis of THP1 cells, as assessed by flow cytometry of Annexin V cell surface expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 5. Pharmacokinetic parameters of gTAb in monkey plasma following a single IV dose of hB6H12.3 (1 mg/kg) or SGN-CD47M (10 or 20 mg/kg) as determined by non-compartmental analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 5. Pharmacokinetic parameters of gTAb in monkey plasma following a single IV dose of hB6H12.3 (1 mg/kg) or SGN-CD47M (10 or 20 mg/kg) as determined by non-compartmental analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 14. Induction of ADCC, assessed using FcγRIIIa-V158 Jurkat NFAT reporter cells incubated with CD47-expressing WIL2-S target cells and increasing concentrations of anti-CD47 antibodies or isotype control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 14. Induction of ADCC, assessed using FcγRIIIa-V158 Jurkat NFAT reporter cells incubated with CD47-expressing WIL2-S target cells and increasing concentrations of anti-CD47 antibodies or isotype control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 19. Protease activity of select syngeneic and xenograft tumor models was assessed using an activatable cell-penetrating peptide (ACPP)2 bearing the -IPVSLRSG- cleavage sequenced used in Coil-MMP-mIAP301 and SGN-CD47M antibodies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 19. Protease activity of select syngeneic and xenograft tumor models was assessed using an activatable cell-penetrating peptide (ACPP)2 bearing the -IPVSLRSG- cleavage sequenced used in Coil-MMP-mIAP301 and SGN-CD47M antibodies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 12. Hemagglutination activity of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47M, and an IgG1 isotype control on human red blood cells, as assessed by optical measurement of spot size following incubation with increasing concentrations of antibodies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 12. Hemagglutination activity of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47M, and an IgG1 isotype control on human red blood cells, as assessed by optical measurement of spot size following incubation with increasing concentrations of antibodies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 3. Statistical analysis of tumor growth inhibition from the A20 syngeneic tumor model experiments shown in Figure 1 in the main text.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 3. Statistical analysis of tumor growth inhibition from the A20 syngeneic tumor model experiments shown in Figure 1 in the main text.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 1. Sequences of anti-CD47 antibodies used in these studies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 1. Sequences of anti-CD47 antibodies used in these studies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 18 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 18. Statistical analysis of tumor growth inhibition from xenograft tumor model experiments shown in Figure 3 in the main text.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 18 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 18. Statistical analysis of tumor growth inhibition from xenograft tumor model experiments shown in Figure 3 in the main text.